These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 11961884)

  • 21. Leveraging biotech's drug discovery expertise for neglected diseases.
    Lowell JE; Earl CD
    Nat Biotechnol; 2009 Apr; 27(4):323-9. PubMed ID: 19352364
    [No Abstract]   [Full Text] [Related]  

  • 22. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 23. Should platform companies move toward products?
    Ratner M
    Nat Biotechnol; 1999 Jan; 17(1):16-7. PubMed ID: 9920255
    [No Abstract]   [Full Text] [Related]  

  • 24. Advice for partnering with pharma.
    Howard K
    Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421
    [No Abstract]   [Full Text] [Related]  

  • 25. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 26. Deal watch: M&A activity in 2009.
    Walker J
    Nat Rev Drug Discov; 2010 Feb; 9(2):95. PubMed ID: 20118956
    [No Abstract]   [Full Text] [Related]  

  • 27. Start-ups weigh benefits of corporate incubators.
    Waltz E
    Nat Biotechnol; 2008 Mar; 26(3):254-5. PubMed ID: 18327219
    [No Abstract]   [Full Text] [Related]  

  • 28. The lengthening handshake.
    Osborne R
    Nat Biotechnol; 2010 Mar; 28(3):197-9. PubMed ID: 20212476
    [No Abstract]   [Full Text] [Related]  

  • 29. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 30. A time for growth: an interview with Amgen CEO Kevin Sharer. Interview by Paul Hemp.
    Sharer K
    Harv Bus Rev; 2004; 82(7-8):66-74, 186. PubMed ID: 15241953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BIO marches to Congress with growth package in hand.
    Carey K
    Nat Biotechnol; 2011 Sep; 29(9):776-7. PubMed ID: 21904306
    [No Abstract]   [Full Text] [Related]  

  • 32. Biotech industry faces new bottleneck.
    Garber K
    Nat Biotechnol; 2001 Mar; 19(3):184-5. PubMed ID: 11231516
    [No Abstract]   [Full Text] [Related]  

  • 33. DPI delivers biotechnology superstore. Discovery Partners International.
    Glaser V
    Nat Biotechnol; 1998 Dec; 16(13):1302. PubMed ID: 9853596
    [No Abstract]   [Full Text] [Related]  

  • 34. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 35. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 36. An embargoed Cuban science.
    Smith C
    Genet Anal; 1999 Nov; 15(3-5):71-2. PubMed ID: 10596742
    [No Abstract]   [Full Text] [Related]  

  • 37. The socialite scientist.
    Serwer A
    Fortune; 2002 Apr; 145(8):152-4, 158, 160 passim. PubMed ID: 11961885
    [No Abstract]   [Full Text] [Related]  

  • 38. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 39. Italian biotech too reliant on big pharma.
    Meldolesi A
    Nat Biotechnol; 2004 Aug; 22(8):1047. PubMed ID: 15309759
    [No Abstract]   [Full Text] [Related]  

  • 40. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.